Biopharmaceutical Company
Appears in 1 story
Imcivree launches in largest indication; monitors GLP-1 competition in obesity space
For patients who gained severe, uncontrollable weight after brain tumor surgery—often as children—there has never been an approved medication. That changed on March 19, 2026, when the Food and Drug Administration (FDA) approved Imcivree (setmelanotide) for acquired hypothalamic obesity, a condition affecting roughly 10,000 Americans whose damaged hypothalamus makes diet and exercise essentially useless. In clinical trials, patients lost 18.4% more body mass than those on placebo over one year. Two weeks later, on April 1, the FDA approved Eli Lilly's Foundayo (orforglipron), the first GLP-1 pill taken without food restrictions, achieving 12.4% weight loss.
Updated Apr 1
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
